Thyroid Cancer Treatments

Find Thyroid Cancer Treatments

Generic Name

Liothyronine

Brand Names
Cytomel, Liomny
FDA approval date: May 08, 1956
Classification: l-Triiodothyronine
Form: Injection, Tablet

What is Cytomel (Liothyronine)?

CYTOMEL is an L-triiodothyronine indicated for: Hypothyroidism: As replacement in primary , secondary , and tertiary congenital or acquired hypothyroidism.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease

Summary: This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimu...

Novel Approaches to the Treatment of Hypothyroidism

Summary: Hypothyroidism is a common condition, more frequent in females, associated with excess of cardiovascular risk and poor quality of life not completely abrogated by treatment with levothyroxine. There is an unmet need to define a safe, effective, and feasible regimen to be applied in large trials aimed at assessing levothyroxine/liothyronine combination therapy in patients living with hypothyroidism...

Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine

Summary: Hypothyroidism is a thyroid disorder and one of the most common endocrine disorders. Hypothyroidism can have multiple causes; most patients suffer from primary autoimmune hypothyroidism (Hashimoto's disease), but also central hypothyroidism, hypothyroidism after total thyroidectomy due to thyroid carcinoma, or hypothyroidism due to therapy of Graves' disease occur. Most patients with hypothyroidis...

Brand Information

    Cytomel (liothyronine sodium)
    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
    • Thyroid hormones, including CYTOMEL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
    • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
    • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects
    1DOSAGE FORMS AND STRENGTHS
    Tablets (round, white to off-white) available as follows:
    • 5 mcg: debossed with KPI on one side and 115 on the other side
    • 25 mcg: scored on one side and debossed with KPI and 116 on the other side
    • 50 mcg: scored on one side and debossed with KPI and 117 on the other side
    2CONTRAINDICATIONS
    CYTOMEL is contraindicated in patients with uncorrected adrenal insufficiency
    3ADVERSE REACTIONS
    Adverse reactions associated with CYTOMEL therapy are primarily those of hyperthyroidism due to therapeutic overdosage
    General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
    Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
    Musculoskeletal: tremors, muscle weakness and cramps
    Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
    Respiratory: dyspnea
    Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests
    Dermatologic: hair loss, flushing
    Endocrine: decreased bone mineral density
    Reproductive: menstrual irregularities, impaired fertility
    4OVERDOSAGE
    The signs and symptoms of overdosage are those of hyperthyroidism
    Reduce the CYTOMEL dose or temporarily discontinued if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status.
    For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or
    5DESCRIPTION
    CYTOMEL tablets contain the active ingredient, liothyronine (L-triiodothyronine or LT
    Chemical Structure
    CYTOMEL tablets contain liothyronine sodium equivalent to liothyronine in 5 mcg, 25 mcg, and 50 mcg. Inactive ingredients consist of calcium sulfate, corn starch, gelatin, stearic acid, sucrose and talc.
    6HOW SUPPLIED/STORAGE AND HANDLING
    CYTOMEL tablets (round, white to off-white) are supplied as follows:
    7PRINCIPAL DISPLAY PANEL - 5 mcg Tablet Bottle Label
    NDC 60793-115-01
    Pfizer
    CYTOMEL®
    liothyronine sodium tablets
    5 mcg
    100 Tablets
    PRINCIPAL DISPLAY PANEL - 5 mcg Tablet Bottle Label
    8PRINCIPAL DISPLAY PANEL - 25 mcg Tablet Bottle Label
    NDC 60793-116-01
    Pfizer
    CYTOMEL®
    liothyronine sodium tablets
    25 mcg
    100 Tablets
    PRINCIPAL DISPLAY PANEL - 25 mcg Tablet Bottle Label
    9PRINCIPAL DISPLAY PANEL - 50 mcg Tablet Bottle Label
    NDC 60793-117-01
    Pfizer
    CYTOMEL®
    liothyronine sodium tablets
    50 mcg
    100 Tablets
    PRINCIPAL DISPLAY PANEL - 50 mcg Tablet Bottle Label